Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial

Choueiri, 2017, Systemic therapy for metastatic renal-cell carcinoma, N Engl J Med., 376, 354, 10.1056/NEJMra1601333 Rini, 2009, Resistance to targeted therapy in renal-cell carcinoma, Lancet Oncol., 10, 992, 10.1016/S1470-2045(09)70240-2 Golshayan, 2009, Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy, J Clin Oncol., 27, 235, 10.1200/JCO.2008.18.0000 Keskin, 2017, Outcomes of patients with renal cell carcinoma and sarcomatoid dedifferentiation treated with nephrectomy and systemic therapies: comparison between the cytokine and targeted therapy eras, J Urol., 198, 530 de Peralta-Venturina, 2001, Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases, Am J Surg Pathol., 25, 275, 10.1097/00000478-200103000-00001 Shuch, 2012, Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies, Oncologist., 17, 46, 10.1634/theoncologist.2011-0227 Joseph, 2015, PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation, Cancer Immunol Res., 3, 1303, 10.1158/2326-6066.CIR-15-0150 Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med., 373, 1803, 10.1056/NEJMoa1510665 Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med., 378, 1277, 10.1056/NEJMoa1712126 Vaishampayan, 2019, Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial, J Immunother Cancer., 7, 275, 10.1186/s40425-019-0746-2 Roland, 2009, Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer, PLoS One., 4, e7669, 10.1371/journal.pone.0007669 Hirsch, 2020, Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma, Drugs., 80, 1169, 10.1007/s40265-020-01327-7 Motzer, 2019, Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med., 380, 1103, 10.1056/NEJMoa1816047 Bakouny, 2019, Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC) [abstract], J Clin Oncol., 37, 4514, 10.1200/JCO.2019.37.15_suppl.4514 McGregor, 2020, Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features, J Clin Oncol., 38, 63, 10.1200/JCO.19.01882 Rini, 2021, Atezolizumab plus bevacizumab versus sunitinib for patients with untreated metastatic renal cell carcinoma and sarcomatoid features: a prespecified subgroup analysis of the IMmotion151 clinical trial, Eur Urol., 79, 659, 10.1016/j.eururo.2020.06.021 Rini, 2019, Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study [abstract], J Clin Oncol., 37, 4500, 10.1200/JCO.2019.37.15_suppl.4500 Tannir, 2021, Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma, Clin Cancer Res., 27, 78, 10.1158/1078-0432.CCR-20-2063 Bakouny, 2021, Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma, Nat Commun., 12, 808, 10.1038/s41467-021-21068-9 Motzer, 2020, Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial, Nat Med., 26, 1733, 10.1038/s41591-020-1044-8 Jerby-Arnon, 2018, A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade, Cell., 175, 984, 10.1016/j.cell.2018.09.006 Puram, 2017, Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer, Cell., 171, 1611, 10.1016/j.cell.2017.10.044 Lukashev, 2006, Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy, Cancer Res., 66, 9617, 10.1158/0008-5472.CAN-06-0217 Messina, 2012, 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?, Sci Rep., 2, 765, 10.1038/srep00765 McDermott, 2018, Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma, Nat Med., 24, 749, 10.1038/s41591-018-0053-3 Chakravarthy, 2018, TGF-beta-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure, Nat Commun., 9, 4692, 10.1038/s41467-018-06654-8 Zilionis, 2019, Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species, Immunity., 50, 1317, 10.1016/j.immuni.2019.03.009 Miao, 2019, Adaptive immune resistance emerges from tumor-initiating stem cells, Cell., 177, 1172, 10.1016/j.cell.2019.03.025 Geng, 2012, DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy, Dev Cell., 22, 38, 10.1016/j.devcel.2011.11.013 Bindea, 2013, Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer, Immunity., 39, 782, 10.1016/j.immuni.2013.10.003 Iglesia, 2014, Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer, Clin Cancer Res., 20, 3818, 10.1158/1078-0432.CCR-13-3368 Palmer, 2006, Cell-type specific gene expression profiles of leukocytes in human peripheral blood, BMC Genomics., 7, 115, 10.1186/1471-2164-7-115 Rody, 2009, T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers, Breast Cancer Res., 11, R15, 10.1186/bcr2234 Rody, 2011, A clinically relevant gene signature in triple negative and basal-like breast cancer, Breast Cancer Res., 13, R97, 10.1186/bcr3035 Schmidt, 2008, The humoral immune system has a key prognostic impact in node-negative breast cancer, Cancer Res., 68, 5405, 10.1158/0008-5472.CAN-07-5206 Fan, 2011, Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures, BMC Med Genomics., 4, 3, 10.1186/1755-8794-4-3 Kardos, 2016, Claudin-low bladder tumors are immune infiltrated and actively immune suppressed, JCI Insight., 1, e85902, 10.1172/jci.insight.85902 Beck, 2009, The macrophage colony-stimulating factor 1 response signature in breast carcinoma, Clin Cancer Res., 15, 778, 10.1158/1078-0432.CCR-08-1283 2013, Comprehensive molecular characterization of clear cell renal cell carcinoma, Nature., 499, 43, 10.1038/nature12222 Zou, 2005, Regularization and variable selection via the elastic net, J R Stat Soc Series B Stat Methodol., 67, 301, 10.1111/j.1467-9868.2005.00503.x Huang, 2018, Evaluating treatment effect based on duration of response for a comparative oncology study, JAMA Oncol., 4, 874, 10.1001/jamaoncol.2018.0275 Huang, 2020, Analysis of response data for assessing treatment effects in comparative clinical studies, Ann Intern Med., 173, 368, 10.7326/M20-0104 Chen, 2018, Profiling tumor infiltrating immune cells with CIBERSORT, Methods Mol Biol., 1711, 243, 10.1007/978-1-4939-7493-1_12 Iacovelli, 2020, Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: a meta-analysis of randomised clinical trials with immune checkpoint inhibitors, Eur J Cancer., 136, 195, 10.1016/j.ejca.2020.06.008 Tirosh, 2016, Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq, Science., 352, 189, 10.1126/science.aad0501 Peng, 2020, The inhibitory PVRL1/PVR/TIGIT axis in immune therapy for hepatocellular carcinoma, Gastroenterology., 159, 434, 10.1053/j.gastro.2020.06.024 Johnston, 2014, The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function, Cancer Cell., 26, 923, 10.1016/j.ccell.2014.10.018 He, 2017, CD155T/TIGIT signaling regulates CD8+ T-cell metabolism and promotes tumor progression in human gastric cancer, Cancer Res., 77, 6375, 10.1158/0008-5472.CAN-17-0381 Rodriguez-Abreu, 2020, Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE), J Clin Oncol., 38, 9503, 10.1200/JCO.2020.38.15_suppl.9503 Chauvin, 2020, TIGIT in cancer immunotherapy, J Immunother Cancer., 8, e000957, 10.1136/jitc-2020-000957